Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 281

1.

Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials.

Sitole M, Silva M, Spooner L, Comee MK, Malloy M.

Clin Ther. 2013 Feb;35(2):190-7. doi: 10.1016/j.clinthera.2012.12.017. Epub 2013 Jan 29.

PMID:
23369368
2.

Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis.

Cooper C, Lester R, Thorlund K, Druyts E, El Khoury AC, Yaya S, Mills EJ.

QJM. 2013 Feb;106(2):153-63. doi: 10.1093/qjmed/hcs214. Epub 2012 Nov 17.

3.

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.

Manns MP, Markova AA, Calle Serrano B, Cornberg M.

Liver Int. 2012 Feb;32 Suppl 1:27-31. doi: 10.1111/j.1478-3231.2011.02725.x. Review.

PMID:
22212568
4.

Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.

Ferenci P, Reddy KR.

Antivir Ther. 2011;16(8):1187-201. doi: 10.3851/IMP1934. Review.

PMID:
22155901
5.

Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?

Pascale A, Serfaty L.

J Hepatol. 2013 Feb;58(2):391-4. doi: 10.1016/j.jhep.2012.09.023. Epub 2012 Oct 9.

6.

Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?

Shiffman ML, Esteban R.

Liver Int. 2012 Feb;32 Suppl 1:54-60. doi: 10.1111/j.1478-3231.2011.02718.x. Review.

PMID:
22212573
7.

Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.

Wedemeyer H, Forns X, Hézode C, Lee SS, Scalori A, Voulgari A, Le Pogam S, Nájera I, Thommes JA.

PLoS One. 2016 Jan 11;11(1):e0145409. doi: 10.1371/journal.pone.0145409. eCollection 2016.

8.

A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 Hepatitis C virus.

Taieb V, Pacou M, Ho S, Pettré S, Van Sanden S, Pisini M, Ustianowski A, Mehnert A.

J Med Econ. 2015;18(10):787-96. doi: 10.3111/13696998.2015.1046880. Epub 2015 May 26. Review.

PMID:
25934147
9.

Triple therapy with boceprevir or telaprevir for prior HCV non-responders.

Asselah T.

Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):455-62. doi: 10.1016/j.bpg.2012.09.003.

PMID:
23199504
10.

Boceprevir: a protease inhibitor for the treatment of hepatitis C.

Chang MH, Gordon LA, Fung HB.

Clin Ther. 2012 Oct;34(10):2021-38. doi: 10.1016/j.clinthera.2012.08.009. Epub 2012 Sep 11. Review.

PMID:
22975763
11.

Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors.

Coppola N, Pisaturo M, Sagnelli C, Sagnelli E, Angelillo IF.

PLoS One. 2014 Apr 11;9(4):e94542. doi: 10.1371/journal.pone.0094542. eCollection 2014.

12.

Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study.

Bailly F, Virlogeux V, Dufour C, Pradat P, Hézode C, Larrey D, Alric L, Samuel D, Bourlière M, Métivier S, Zarski JP, Fontaine H, Loustaud-Ratti V, Serfaty L, Bronowicki JP, Carrat F, Zoulim F; CUPIC Study Group..

Clin Res Hepatol Gastroenterol. 2015 Sep;39(4):443-50. doi: 10.1016/j.clinre.2014.12.007. Epub 2015 Jan 27.

PMID:
25636238
13.

Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.

Sterling RK, Kuo A, Rustgi VK, Sulkowski MS, Stewart TG, Fenkel JM, El-Genaidi H, Mah'moud MA, Abraham GM, Stewart PW, Akushevich L, Nelson DR, Fried MW, Di Bisceglie AM.

Aliment Pharmacol Ther. 2015 Apr;41(7):671-85. doi: 10.1111/apt.13095. Epub 2015 Jan 28.

14.

Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.

Perry CM.

Drugs. 2012 Mar 26;72(5):619-41. doi: 10.2165/11208370-000000000-00000. Review.

PMID:
22439668
15.

A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.

Chen EY, Sclair SN, Czul F, Apica B, Dubin P, Martin P, Lee WM.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):1014-20.e1-2. doi: 10.1016/j.cgh.2013.03.032. Epub 2013 Apr 16.

PMID:
23602817
16.

Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.

Blázquez-Pérez A, San Miguel R, Mar J.

Pharmacoeconomics. 2013 Oct;31(10):919-31. doi: 10.1007/s40273-013-0080-3.

PMID:
24000086
17.

Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.

Foote BS, Spooner LM, Belliveau PP.

Ann Pharmacother. 2011 Sep;45(9):1085-93. doi: 10.1345/aph.1P744. Epub 2011 Aug 9. Review.

PMID:
21828346
18.

A new era in the treatment of chronic hepatitis C infection.

Jothimani D, Chandy GM, Conjeevaram H.

Indian J Gastroenterol. 2013 Mar;32(2):71-9. doi: 10.1007/s12664-012-0254-5. Epub 2012 Sep 28. Review.

PMID:
23054947
19.

Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.

Forestier N, Zeuzem S.

Liver Int. 2012 Feb;32 Suppl 1:44-50. doi: 10.1111/j.1478-3231.2011.02720.x. Review.

PMID:
22212571
20.

A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy.

Burton JR Jr, O'Leary JG, Verna EC, Saxena V, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS Jr, Terrault NA.

J Hepatol. 2014 Sep;61(3):508-14. doi: 10.1016/j.jhep.2014.04.037. Epub 2014 May 5.

Supplemental Content

Support Center